Early Tumor Response to Hsp90 Therapy Using HER2 PET: Comparison with 18F-FDG PET
作者： Peter M. Smith-Jones , David Solit , Neal Rosen , Farzana Afroze , Steven M. Larson
DOI:
关键词:
摘要: We compared 68Ga-DOTA-F(ab′)2-herceptin (DOTA is 1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴-tetraacetic acid [HER2 PET]) and 18F-FDG PET for imaging of tumor response to the heat shock protein 90 (Hsp90) inhibitor 17-allylamino-17-demethoxygeldanamycin (17AAG). Methods: Mice bearing BT474 breast xenografts were scanned with HER2 before after 17AAG treatment then biweekly up 3 wk. Results: Within 24 h treatment, a significant decrease in was measured by PET, whereas uptake, measure glycolysis, unchanged. Marked growth inhibition occurred treated tumors but became evident only 11 d treatment. Thus, Her2 downregulation occurs independently changes glycolysis therapy, reduction more accurately predicts subsequent inhibition. Conclusion: an earlier predictor therapy than PET.
参考文章(27)
Len Neckers, Heat shock protein 90 inhibition by 17-allylamino-17- demethoxygeldanamycin: a novel therapeutic approach for treating hormone-refractory prostate cancer. Clinical Cancer Research. ,vol. 8, pp. 962- 966 ,(2002)
Wu-Chou Su, Shu-Chu Shiesh, Hsiao-Sheng Liu, Chiung-Yu Chen, Nan-Haw Chow, Xi-Zhang Lin, Expression of Oncogene Products HER2/Neu and Ras and Fibrosis-Related Growth Factors bFGF, TGF-β, and PDGF in Bile from Biliary Malignancies and Inflammatory Disorders Digestive Diseases and Sciences. ,vol. 46, pp. 1387- 1392 ,(2001) , 10.1023/A:1010619316436
David B. Solit, Carlos Cordon-Cardo, David Verbel, Howard I. Scher, Brian Higgins, Neal Rosen, Pamela N. Münster, Fuzhong F. Zheng, David B. Agus, Maria Drobnjak, Glenn Heller, William Tong, 17-Allylamino-17-demethoxygeldanamycin Induces the Degradation of Androgen Receptor and HER-2/neu and Inhibits the Growth of Prostate Cancer Xenografts Clinical Cancer Research. ,vol. 8, pp. 986- 993 ,(2002)
J. Czernin, Clinical applications of FDG-PET in oncology. Acta Medica Austriaca. ,vol. 29, pp. 162- 170 ,(2002) , 10.1046/J.1563-2571.2002.02042.X
Min Yao, Michael M. Graham, Russell B. Smith, Kenneth J. Dornfeld, Mark Skwarchuk, Henry T. Hoffman, Gerry F. Funk, Scott M. Graham, Yusuf Menda, John M. Buatti, Value of FDG PET in assessment of treatment response and surveillance in head-and-neck cancer patients after intensity modulated radiation treatment: A preliminary report International Journal of Radiation Oncology Biology Physics. ,vol. 60, pp. 1410- 1418 ,(2004) , 10.1016/J.IJROBP.2004.05.058
Udai Banerji, Michael Walton, Florence Raynaud, Rachel Grimshaw, Lloyd Kelland, Melani Valenti, Ian Judson, Paul Workman, Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models. Clinical Cancer Research. ,vol. 11, pp. 7023- 7032 ,(2005) , 10.1158/1078-0432.CCR-05-0518
A. Skálová, I. Stárek, V. Kučerová, P. Szépe, L. Plank, Salivary Duct Carcinoma - A Highly Aggressive Salivary Gland Tumor with HER-2/neu Oncoprotein Overexpression Pathology Research and Practice. ,vol. 197, pp. 621- 626 ,(2001) , 10.1078/0344-0338-00136
Len Neckers, Hsp90 inhibitors as novel cancer chemotherapeutic agents Trends in Molecular Medicine. ,vol. 8, pp. S55- S61 ,(2002) , 10.1016/S1471-4914(02)02316-X
G Speer, K Cseh, G Winkler, I Takács, Z Nagy, P Lakatos, Oestrogen and vitamin D receptor (VDR) genotypes and the expression of ErbB-2 and EGF receptor in human rectal cancers European Journal of Cancer. ,vol. 37, pp. 1463- 1468 ,(2001) , 10.1016/S0959-8049(01)00139-3
Wedad Hanna, Testing for HER2 status. Oncology. ,vol. 61, pp. 22- 30 ,(2001) , 10.1159/000055398